NFKB1 and urticaria: In an ovalbumin (OVA)-induced urticaria murine model, LG-1 administration demonstrated marked reductions in serum UA and hypoxanthine concentrations, alleviated clinical manifestations, and suppressed inflammation via TLR4-NF-κB pathway inhibition.